Early research (Phase 1)Ended earlyNCT02370888
What this trial is testing
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
Who this might be right for
Leukemia, MyeloidMyelodysplastic Syndromes
University of Florida 11